S'abonner

Efficacy of oral rinse and other detection methods in detecting oral human papillomavirus infections: The Oromouth cohort study - 05/03/25

Doi : 10.1016/j.jinf.2025.106438 
Bethany Hillier a, b, Tim Waterboer c, Jill Brooks d, e, Paul Nankivell d, e, Ridhi Agarwal a, b, Ahmad K. Abou-Foul d, e, Tessa Fulton-Lieuw d, e, Caroline Kristunas d, e, Alex Vorsters f, Joanna Parish b, e, Hisham Mehanna d, e,
a Biostatistics, Evidence Synthesis, Test Evaluation And Prediction Modelling (BESTEAM), Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, United Kingdom 
b NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, United Kingdom 
c German Cancer Research Center (DKFZ), Heidelberg, Germany 
d Institute of Head and Neck Studies and Education, College of Medicine and Health, University of Birmingham, United Kingdom 
e Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, United Kingdom 
f Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium 

Correspondence to: Institute of Head and Neck Studies and Education, College of Medical and Dental Sciences, University of Birmingham, B15 2TT, United Kingdom.Institute of Head and Neck Studies and Education, College of Medical and Dental Sciences, University of BirminghamB15 2TTUnited Kingdom

Summary

Objectives

Human papillomavirus (HPV) mediated oropharyngeal cancer (OPC) incidence has increased dramatically. Accurate oral HPV prevalence data are essential for assessing population epidemiology, vaccination and screening programmes. As oral rinse is the most commonly used primary outcome measure for estimating oral HPV prevalence, we aimed to compare the efficacy of oral rinse against other detection methods.

Methods

The Oromouth study enrolled 945 participants, aged 0–65 years (63% female), undergoing tonsillectomy for non-malignant indications, without OPC diagnoses. Samples from oral rinse, pharyngeal wall, tongue base, tonsil tissue and blood were collected. HPV DNA in oral samples was centrally tested via polymerase chain reaction, and serology samples for HPV antibodies. Statistical analyses assessed prevalence, detection rates and ratios.

Results

Combining all four oral collection sites, high-risk (HR)-HPV and any HPV prevalence were 4·3% and 18%, respectively. HR-HPV prevalence was similar between males (4·1%) and females (4·5%). Oral rinse had the highest HR-HPV (4·0%) and any HPV detection rates (16%), but still missed 73% (11/15) identified as HR-HPV-positive by other oral sites. Compared to oral rinse alone, an additional 38% (11/29) HR-HPV infections were picked up by the other three oral collection methods. Addition of serology testing did not result in substantial improvement.

Conclusions

Of the four oral sites, oral rinse demonstrates the highest detection rates by far but has important limitations. These findings should be taken into consideration when estimating oral HPV infection rates, especially for vaccination studies and screening programmes.

Le texte complet de cet article est disponible en PDF.

Highlights

Oral rinse is the most common measure for estimating oral HPV prevalence.
We compared oral rinse to pharyngeal wall and tongue base brushes, & tonsil tissue.
Combining all four oral sites, any HPV and HR-HPV prevalence were 18% and 4.3%.
Oral rinse misses 73% (11/15) of HR-HPV cases detected by the other oral sites.
All 4 sample types combined improve HR-HPV detection over oral rinse alone by 38%.

Le texte complet de cet article est disponible en PDF.

Keywords : Head and neck cancer, HNC, Oral rinse, Detection, Oropharyngeal cancer, OPC, Human papillomavirus, HPV


Plan


© 2025  The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 90 - N° 3

Article 106438- mars 2025 Retour au numéro
Article précédent Article précédent
  • Measles-mumps-rubella vaccination at 6 months of age and the risk of atopic disease in the first year of life: Results from a Danish placebo-controlled randomised trial
  • Anne Cathrine Zimakoff, Andreas Jensen, Michelle Malon, Jesper Kiehn Sørensen, Dorthe Maria Vittrup, Signe Kjeldgaard Jensen, Emma Therese Bay, Jannet Svensson, Lone Graff Stensballe
| Article suivant Article suivant
  • Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response
  • C.C.A. Noble, E. McDonald, S. Nicholson, S. Biering-Sørensen, L.F. Pittet, A.L. Byrne, J. Croda, M. Dalcolmo, M.V.G. Lacerda, M. Lucas, D.J. Lynn, C. Prat Aymerich, P.C. Richmond, A. Warris, N. Curtis, N.L. Messina, the BRACE Trial Consortium Group

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.